Business Wire

UK National Institute for Health and Care Excellence (NICE) Updates Endobronchial Valve Treatment Guidance to Standard Care

Del

Pulmonx® Corp. today announced that the UK’s National Institute for Health and Care Excellence (NICE) has updated its guidance for endobronchial valves used to treat severe emphysema, an advanced form of chronic obstructive pulmonary disease (COPD), and now considers current evidence sufficient to support routine use.

The change in NICE guidance is based on safety and efficacy data from multiple randomized clinical trials evaluating Zephyr® Endobronchial Valves (EBV®), which have demonstrated benefits for patients in quality of life, exercise capacity and lung function, as well as long-term safety. In fact, four randomized controlled trials of the Zephyr EBV (BeLieVeR-HiFI, TRANSFORM, STELVIO and IMPACT) provide a significant body of evidence supporting the ability of the treatment to significantly improve lung function, exercise tolerance and quality of life in emphysema patients with no collateral ventilation, as assessed with the Chartis System.1,2,3,4

“In light of the high burden of symptoms, progressive nature of emphysema and poor prognosis for patients, the NICE decision means that patients with severe emphysema should be referred to specialists to determine if they are good candidates for endobronchial valves or other interventions,” said Pallav Shah, MD, consultant physician in respiratory medicine at Royal Brompton Hospital and Chelsea & Westminster Hospital, London.

The British Lung Foundation estimates that in the UK, 1.2 million people are living with diagnosed COPD and almost 30,000 die from the disease every year.5 Roughly one-third of COPD patients have a form of the disease called emphysema.6 Emphysema causes damage to the alveoli, the air sacs in the lungs, which allows air to escape and prevents patients from taking in full breaths. This chronic breathlessness makes even the simplest daily activities difficult, such as washing, eating, walking and household chores, and often leads to patients becoming housebound and depressed. In fact, the quality of life for emphysema patients is worse than that for lung cancer.7

Zephyr EBVs are tiny, minimally-invasive, one-way valves placed via a flexible bronchoscope in airways in the lungs to occlude diseased regions and reduce lung hyperinflation. As a result, the remaining healthier regions can function more efficiently, enabling better breathing and an improved quality of life for patients.

Zephyr EBVs are routinely used in Europe and Australia as a treatment for severe emphysema. The treatment has been included in influential international guidelines from such groups as the Global Initiative for Chronic Obstructive Lung Disease (GOLD).8 The well-known independent Cochrane Airways Group also published a review of the available evidence earlier this year and concluded that, with proper patient selection, bronchoscopic lung volume reduction techniques – such as the Zephyr EBV – should be considered for severe emphysema patients when medical therapy has failed.9

Germany and Switzerland have supported EBV use in eligible patients for several years, and late last month, the Dutch organization for reimbursement – the Zorginstituut Nederland – ruled that EBVs are considered an effective treatment in adult patients with severe emphysema and will now be covered by the government.10

“These decisions will increase patient access to our proven and minimally-invasive Zephyr technology, which has the potential to significantly improve the quality of life for patients,” said Pulmonx CEO Glen French.

Over the past 10 years, more than 50,000 Zephyr EBVs have been implanted globally in more than 12,000 patients. To view a video of the Zephyr EBV procedure, click here.

About Pulmonx

Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com.

The Zephyr EBVSystem is an investigational device in the United States. Limited by U.S. law to investigational use only.

1. Klooster K, Ten Hacken NHT, Hartman JE, Kerstjens HAM, Van Rikxoort EM, Slebos DJ. Endobronchial valves for emphysema without interlobar collateral ventilation. N Engl J Med 2015; 373:2325-2335.
2. Davey C, Zoumot Z, Jordan S, McNulty W, Carr D, Hind M, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet 2015;386(9998):1066-73.
3. Kemp SV, et al. A multicenter RCT of Zephyr Endobronchial Valve treatment in heterogeneous emphysema (TRANSFORM). Am J Respir Crit Care Med 2017;https://doi.org/10.1164/rccm.201707-1327OC
4. Valipour A, et al. Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT study. Am J Respir Crit Care Med 2016;194(9):1073-1082.
5. https://statistics.blf.org.uk/copd
6. http://www.lung.org/assets/documents/research/copd-trend-report.pdf
7. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000;55(12):1000-1006.
8. http://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf
9. http://www.cochrane.org/CD012158/AIRWAYS_bronchoscopic-lung-volume-reduction-procedures-moderate-severe-chronic-obstructive-pulmonary-disease
10. https://www.zorginstituutnederland.nl/publicaties/standpunten/2017/09/14/standpunt-endobronchiale-longvolumereductie-middels-eenrichtingskleppen-bij-ernstig-longemfyseem

Contact information

Chronic Communications
Michelle McAdam
(949) 545-6654 or (310) 902-1274
michelle@chronic-comm.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

OpenGate Capital Launches OGx Digital Transformation Capability16.1.2019 08:00Pressemelding

OpenGate Capital, a global private equity firm, announced today that it has launched OGx, a newly formed digital innovation and business transformation growth capability as part of the firm’s commitment to untap the full potential of its acquired businesses. Developed during 2018, OGx represents the combined power of the firm’s operational excellence best practices with applied exponential technologies and business model innovation to yield the XPotential™ for select investments. Andrew Nikou, OpenGate Capital’s founder and CEO stated, “We are constantly looking for innovative and differentiated ways to accelerate profitable growth in the businesses we acquire. We are excited to launch OGx after successfully piloting it during 2018, recognizing that in this age of increased technology and business disruption, sustainable and scalable value creation within our holding period must go well beyond traditional operating drivers. We believe that a great deal of upside can be created from tak

Gemalto to Produce Secure and Innovative Healthcare Cards for Quebec16.1.2019 06:00Pressemelding

Gemalto (Euronext NL0000400653 - GTO), the world leader in digital security, and the Société de l'assurance automobile du Québec (SAAQ) have been chosen to produce secure and innovative health insurance cards for the Régie de l'assurance maladie du Québec (RAMQ). RAMQ delivers 2.3 million healthcare cards to citizens, and the SAAQ provides 1.7 million driver’s license and identity cards through production with Gemalto. Optimizing government services across industries By choosing the SAAQ and its existing contract with Gemalto, the Quebec healthcare authorities can avoid duplication and promote sharing of expertise between agencies. The province can also leverage the existing infrastructure and issue both healthcare cards and driver’s licenses at the same time, maximizing cost savings and ensuring quicker delivery to their citizens. A focus on security and convenience for Quebec’s citizens Gemalto’s secure card will be the first of its kind to undergo embossing and laser engraving at th

Stewart Title Ltd. Appoints Ferky Azib to General Counsel and Corporate Secretary16.1.2019 05:00Pressemelding

Stewart Title Ltd., the underwriter for Stewart’s transactions in the United Kingdom, Europe and Australia, announced today the promotion of Ferky Azib to General Counsel. In her new position, Ms. Azib will provide counsel and guidance on all legal matters for Stewart Title Limited’s expanding operations. She will be involved in the development and implementation of corporate policies as well as oversee corporate governance and regulatory compliance. Ms. Azib will also serve on the Stewart Title Limited Board of Directors as Corporate Secretary. “Ms. Azib has the knowledge and experience required to guide the company through all the regulatory requirements in the countries within which we operate,” said Steven Lessack, chief executive officer, Stewart Title Limited. “Equally important, she has developed an excellent rapport with both clients and staff, providing valued insight and support. It is a pleasure to have her on board as we move forward with our growth in this region.” Ms. Azi

PMC Group International Announces Acquisition of Product Line from Solvay, SA16.1.2019 00:33Pressemelding

PMC Ouvrie SAS, France, a wholly owned subsidiary of PMC Group International Inc., which is an independent arm of PMC Group Inc., announced the acquisition of a hydrocolloid product line from the Belgium based Solvay, SA. These products will be sold globally to the home and personal care (HPC), industrial and coatings markets under the trade names Rhodicare CFT, Rhodicare D, Rhodicare H, Rhodicare S, Rhodicare T, Rhodicare XC, Rhodopol 23, Rhodopol G, Rhodopol T, Rhodopol TG, Rhodopol Extra 2, and Rhodopol Extra 2 Clear. “The acquisition of these products made by fermentation processes emphasizes our increasing interest in products made by green chemistry and biological processes,” said Dr. Raj Chakrabarti, Head of PMC Group International. “The acquired hydrocolloids fit synergistically with the functional product lines of PMC Ouvrie, which has long been a leading supplier of defoamers to bio-based process technologies,” he added. ABOUT PMC PMC Group is a US based growth oriented, dive

TurbineAero, Inc. Announces Acquisition of APU Piece Part Repair Business from the Triumph Group15.1.2019 23:51Pressemelding

TurbineAero, a portfolio company of The Gores Group, announced today the acquisition of the APU piece part repair product line (“RPL”) from Triumph Aviation Services Asia, Ltd. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190115005959/en/ TurbineAero Repair–Asia, APU Operations Team (Photo: Business Wire) The acquisition of this business segment integrates APU piece part repair into the APU Systems MRO in TurbineAero’s Asia facility which increases in-house capabilities, improves turn-times and assures extra cost reduction. Effective immediately, the integration will take place in TurbineAero Asia’s new Thailand based 80,000 square foot facility which will house up to 250 employees and will handle high technological testing, maintenance, repair and overhaul activities for aircraft components and systems for our worldwide customers, including APU MRO, LRUs and APU part repair. “We are delighted to add the APU piece part rep

INDYCAR Names NTT as Entitlement Sponsor of IndyCar Series15.1.2019 17:20Pressemelding

INDYCAR announced today during the North American International Auto Show that global information technology and communications leader NTT has signed a multi-year agreement to become the IndyCar Series Title Partner. In addition, NTT becomes the Official Technology Partner of INDYCAR, the IndyCar® Series, Indianapolis Motor Speedway, the Indianapolis 500 and NASCAR’s the Brickyard 400 beginning in 2019. INDYCAR will partner with NTT to deliver digital innovations that enhance the fan experience. These innovations include the evolution of INDYCAR’s mobile application and adoption of NTT’s proprietary Smart Platform to support the sport and its venues in delivering better insights into the racing series. “NTT is proud to be associated with INDYCAR and accelerate the future of smart racing. Technological innovations have the potential to change the sport and fan experience drastically,” said Jun Sawada, President and CEO of NTT. “NTT, along with our partners, aims to bring the Smart World